1 **Title:** Surveillance of colistin-resistance and *mcr genes* in multi-drug resistant

2 Enterobacteriaceae

3

4 **Running Title:** Surveillance of colistin-resistant Enterobacteriaceae

5

6 **Authors:**

7 Yasuhide Kawamoto¹, Norihito Kaku^{1,2}, Norihiko Akamatsu¹, Kei Sakamoto^{1,2}

8 Kosuke Kosai^{1,2}, Yoshitomo Morinaga^{1,2,3}, Norio Ohmagari⁴, Koichi Izumikawa⁵,

9 Yoshihiro Yamamoto⁶, Hiroshige Mikamo⁷, Mitsuo Kaku⁸, Kazunori Oishi^{9,10},

10 Katsunori Yanagihara^{1,2}

11

12 **Affiliations:**

13 ¹Department of Laboratory Medicine, Nagasaki University Hospital, Japan.

14 ²Department of Laboratory Medicine, Nagasaki University Graduate School of

15 Biomedical Sciences, Japan.

16 ³Department of Microbiology, Graduate School of Medicine and Pharmaceutical

17 Sciences, University of Toyama,

18 ⁴Disease Control and Prevention Center, National Center for Global Health and

19 Medicine, Japan.

20 ⁵Department of Infectious Diseases, Nagasaki University Graduate School of

21 Biomedical Sciences, Japan.

22 ⁶Department of Clinical Infectious Diseases, Graduate School of Medicine and

23 Pharmaceutical Sciences for Research, University of Toyama, Japan.

24 ⁷Department of Clinical Infectious Diseases, Aichi Medical University Graduate School

25 of Medicine, Japan.

26 ⁸Department of Infection Control and Laboratory Diagnostics, Tohoku University

27 Graduate School of Medicine, Japan

28 ⁹Infectious Disease Surveillance Center, National Institute of Infectious Diseases

29 Correspondence, Japan

30 ¹⁰Toyama Institute of Health, Japan.

31

32 **Address for correspondence:**

33 Norihito Kaku, Department of Laboratory Medicine, Nagasaki University Graduate

34 School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, Nagasaki 852-8501, Japan;

35 email: norihitk@gmail.com; tel/fax: +81-95-819-7413

36 **Abstract**

37 **Background.** The plasmid-mediated bacterial colistin-resistant (*mcr*) gene is a global
38 concern in clinical health care. This study aimed to clarify the prevalence of colistin
39 resistance through nine *mcr* genes in ESBL-producing and CRE isolated
40 Enterobacteriaceae in Japan.

41 **Methods.** We collected strains from August 2016 to March 2017 from five tertiary
42 hospitals. MICs were measured using the microdilution method. PCR was performed to
43 detect *mcr-1* to *mcr-9* genes in all strains. Additionally, we performed whole-genome
44 sequencing of the *mcr* gene-positive strain.

45 **Results.** The rate of colistin resistance was 7.7%. The *mcr-5* and *mcr-9* gene were
46 detected in one ESBL-producing *E. coli* strain (0.37%) and three CRE strains (1.1%),
47 respectively. Since the ESBL-producing *E. coli* strain was the first clinical strain with
48 *mcr-5* in Japan, whole-genome sequencing analysis was performed for the strain. The
49 sequence type of the *mcr-5* positive strain was ST1642 and it carried two distinct
50 plasmids, ESBL gene-carrying pN-ES-6-1 and *mcr-5.1*-carrying pN-ES-6-2.

51 **Conclusions.** We showed that the frequency of colistin resistance and *mcr*-positive
52 strains is not high in Japan. Since the MIC for colistin was low in the *mcr-5.1* and *mcr-9*
53 gene-positive strain, continuous monitoring of *mcr* genes is necessary.

54 **Keywords.** *mcr-5*; *mcr-9*; colistin; Enterobacteriaceae; Surveillance; Japan

55

56 **Introduction**

57 The emergence and spread of antimicrobial resistance are a global concern. In Japan, a
58 previous study reported that ESBL-producing *Escherichia coli* (*E. coli*) and *Klebsiella*
59 *pneumoniae* (*K. pneumoniae*) strains are spreading, accounting for 23.0% of *E. coli* and
60 10.7% of *K. pneumoniae* infections [1]. Because of the distribution of fluoroquinolone
61 resistant in ESBL-producing *E. coli*, the clinical use of carbapenem is increasing [2, 3].
62 However, in recent years, carbapenem-resistant Enterobacteriaceae (CRE) have become
63 a serious problem worldwide. Some CREs have multidrug resistance against
64 fluoroquinolone as well as beta-lactam [4, 5]. Therefore, colistin, which belongs to the
65 family of polymyxins and has broad-spectrum activity against gram-negative bacteria, is
66 an important antibiotic in the treatment of CRE and ESBL.

67 On the other hand, several colistin resistance mechanisms have been reported. The
68 major colistin resistance mechanisms are as follows: alteration of the LPS moiety
69 resulting in a reduced net negative charge of LPS, increased drug efflux, overexpression
70 of outer membrane protein (OprH), and the formation of capsules (*siaD*, *ompA*, *cps*) [6,
71 7]. Since all of these resistance mechanisms are intrinsic, mutational, and adaptive,
72 colistin resistance is unlikely to spread from cell to cell through delivery of plasmids
73 like ESBL and carbapenemase-producing Enterobacteriaceae (CPE). However, in 2016,

74 the first plasmid-mediated colistin resistance (*mcr*) gene was identified in animals in
75 China [8]. Thereafter, *mcr*-positive Enterobacteriaceae have been identified in healthy
76 people and patients all over the world [9]. In Japan, although there have been some
77 reports on *mcr*-positive *E. coli* in animals and food sources [10-12], there are few
78 studies in humans [13]. In addition, the percentage of colistin resistance in Japan
79 remains unknown because the MIC of colistin in Enterobacteriaceae including ESBL
80 and CRE has not been evaluated.

81 The purpose of this study was to clarify the prevalence of colistin resistance and nine
82 *mcr* genes in ESBL-producing Enterobacteriaceae and CRE isolated from patients in
83 tertiary hospitals in Japan. Additionally, we performed whole-genome sequencing of the
84 *mcr* gene-positive strain.

85

86 **Materials and methods**

87 *Strains*

88 A total of 273 different clinical ESBL-producing Enterobacteriaceae and CRE isolates
89 between August 2016 and March 2017 were collected from five tertiary hospitals
90 representing the Western, Eastern, and Central regions of Japan. Only one isolate per
91 patient was included in this study. *Proteus* spp. and *Providencia rettgeri* were excluded

from analysis, because they are intrinsically resistant to colistin. A total of 180
ESBL-producing strains and 93 CRE strains were collected during the study period. The
ESBL-producing strains contained *E. coli* (81.7%), *Klebsiella pneumoniae* (15.6%) and
Klebsiella oxytoca (2.8%). The CRE strains contained *Klebsiella aerogenes* (45.2%),
Enterobacter cloacae complex (38.7%), *Klebsiella pneumoniae* (11.8%), *E. coli* (2.2%)
and *Citrobacter* spp. (2.2%). The strains were stored in a Microbank tube and placed at
-80°C.

99

100 *Analysis of strains*

Bacteria were identified using MALDI-TOF MS (Bruker Daltonics GmbH, Bremen,
Germany). ESBL production was detected using the BD Phoenix system NMIC-207
panel (Becton Dickinson, Holdrege, USA) according to the manufacturer's instructions.
Carbapenemase genes were evaluated by Xpert Carba-R assay (Cepheid, Sunnyvale,
USA) according to the manufacturer's instructions. MICs were measured using the
microdilution method. Susceptibility was determined according to the CLSI M100-S25
except for colistin, which was interpreted according to the EUCAST version 9.0 (MIC
for susceptible, ≤ 2 mg/L; MIC for resistant, >2 mg/L).

109

110 *Analysis of mcr genes*

111 PCR was performed to detect *mcr-1* to *mcr-9* genes in all strains. DNA was extracted
112 using the boiling method with minor modifications [14]. PCR amplification about *mcr-1*
113 to *mcr-5* was performed under the following conditions: 15 min at 94°C, 25 cycles of 30
114 s at 94°C, 30 s at 58°C, 60 s at 72°C, and 10 min at 72°C for the final extension [15].
115 PCR amplification about *mcr-6* to *mcr-9* was performed under the following conditions:
116 3 min at 95°C, 30 cycles of 30 s at 95°C, 30 s at 55°C, 60 s at 72°C, and 10 min at 72°C
117 for the final extension[16].

118

119 *Whole-genome sequencing*

120 DNA was extracted using the Quick-DNA™ Fecal/Soil Microbe Miniprep kit
121 according to the manufacturer's instructions (Zymo Research, CA, USA).
122 Whole-genome sequencing was performed using NextSeq 500 (Illumina Inc. San Diego
123 CA USA) and GridION X5 (Oxford Nanopore Technologies, Oxford, UK). The *de novo*
124 hybrid assembly of both short-reads (NextSeq 500) and long-reads (GridION X5) was
125 performed using Unicycler v0.4.7 under conservative conditions. CheckM v1.0.12 was
126 used to assess the quality of assembled genomes. The allele sequences and sequence
127 types (STs) were determined according to the *E. coli* database

128 (<http://mlst.warwick.ac.uk/mlst/dbs/Ecoli>). In the plasmid analysis, Prokka v1.13 was
129 used for genome annotation. Antimicrobial resistance genes were identified using
130 ResFinder v3.2 (<https://cge.cbs.dtu.dk/services/ResFinder/>). The bacterial insertion
131 sequence was detected using the IS Finder database (<https://isfinder.biotoul.fr>).
132 PlasmidFinder v2.0.1 was used to determine plasmid incompatibility (Inc) groups.
133 Importing Prokka's annotation result and drawing the plasmid map with Snap Gene
134 v4.3.10 GSL Biotech.

135

136 *Phylogenetic analysis and genetic environment*

137 The *mcr-5*-carrying plasmid sequencing from *Salmonella enterica* (Gene accession no.
138 NC_003277.2), *Salmonella enterica* (Gene accession no. LC488708.01), *Escherichia*
139 *coli* (Gene accession no. BENI01000099.1), pN-ES-6-2 *Escherichia coli* and
140 *Salmonella enterica* (Gene accession no. KY807921.1) were downloaded from
141 GenBank database. Phylogenetic tree and genetic environment were constructed using
142 CLC Genomics Workbench version 21.0.3.

143

144 *Data availability*

145 Raw data were generated at Nagasaki University Hospital. Derived data supporting the
146 findings of this study are available from the corresponding author upon request.

147

148 *Ethics*

149 This study was approved by the Ethics Committee of Nagasaki University Hospital
150 (16072509). Data regarding clinical ESBL-producing Enterobacteriaceae and CRE
151 isolates were anonymized and individually numbered when they were collected from
152 the hospitals.

153

154 **Results**

155 *Colistin Susceptibility*

156 The rate of colistin resistance in all strains was 11.4% (Table 1). The rate of colistin
157 resistance in the CRE strains was higher than that in the ESBL-producing strains (7.7%
158 versus 18.9%, Table 1). The MIC of colistin in both ESBL-producing strains and CRE
159 formed a bimodal distribution (Fig. 1A and B). The *Enterobacter cloacae* complex had
160 the highest rate of colistin resistance (50.0%) (Table 1). The rate of colistin resistance
161 was not significantly different based on site of infection or region where the strain was
162 isolated (Table S1). In the CRE strains, carbapenemase-producing Enterobacteriaceae

163 (CPE) had a higher rate of colistin resistance (40.0%) than non-CPE strains (16.6%)

164 (Fig. 1C).

165

166 *Detection of mcr genes*

167 The 273 strains (ESBL and CRE) were screened using PCR for the presence of the

168 nine *mcr* genes, *mcr-1* to *mcr-9*. The *mcr-5* gene was detected in only one

169 ESBL-producing *E. coli* strain (0.37%), and the *mcr-9* gene was detected in three CRE

170 *Enterobacter cloacae* complex strains (1.1%). The two of three *mcr-9* positive strains

171 were isolated in the same hospital, but the ward and the department were different. All

172 the *mcr* positive strains indicated very low MIC for colistin (Table S2).

173

174 *Whole-genome sequencing of mcr-5 gene-positive strain*

175 Since there were no reports of *mcr-5* positive ESBL-producing *E. coli* infecting

176 humans in Japan, we conducted a detailed analysis by whole-genome sequencing. The

177 draft genome of *mcr-5* gene-positive *E. coli* strain (DDBJ accession no. DRA010253)

178 comprised 5,027,748 bp with an overall GC content of 50.76%. The genome consisted

179 of 22 rRNA operons, 80 tRNA genes, and 4686 protein-coding genes (CDSs). The

180 *mcr-5* gene-positive *E. coli* was classified as ST1642 and *fimH* subtype 31. The isolate

181 harbored two distinct plasmids, pN-ES-6-1 (DDBJ accession no. LC553463, 94901
182 bp), and pN-ES-6-2 (DDBJ accession no. LC553464, 79974 bp). pN-ES6-1 had
183 various resistance genes, including *mph(A)*, *dfrA17*, *bla*_{TEM-1B}, *sul2*, *tet(B)*, *aac(3)-Ild*,
184 *aac(3'')-Ib*, and *aph(6)-Id*, whereas pN-ES-6-2 had only one resistance gene (*mcr-5.1*)
185 (Table 2). The Plasmid Inc. groups and transposons of pN-ES-6-2 were IncF II and
186 TnShfr1 (Tn3-family), respectively (Table 2). Phylogenetic analysis of *mcr-5* carrying
187 plasmid revealed that pN-ES-6-2 showed similarities to *Escherichia coli* (Gene
188 accession no. BENI01000099.1) isolated in Japan, but less to the first reported *mcr-5*
189 carrying plasmid (Gene accession no. KY807921.1, *Salmonella enterica*, Germany)
190 (Figure 3 A). pN-ES-6-2 lacked some major facilitator superfamily (MFS) gene in
191 comparison with other *mcr-5* carrying plasmids (Figure 3 B).

192

193 Discussion

194 In this study, we clarified the prevalence of colistin resistance in ESBL-producing
195 Enterobacteriaceae and CRE. The rates of colistin resistance were 0.7% for *E. coli*,
196 2.6% for *K. pneumoniae*, and 50.0% for *Enterobacter cloacae* complex. Global
197 surveillance in 2015 reported that the resistance rate of colistin was 0.3% in *E. coli*,
198 2.4% in *K. pneumoniae*, and 39.1% in *Enterobacter asburiae* [17]. The Surveillance of

199 Multicenter Antimicrobial Resistance in Taiwan reported that the resistance rate of
200 colistin was 0.3% in *E. coli* and 2.4% in *K. pneumonia* [18]. These results are consistent
201 with our study. Accordingly, in Japan, it is considered that colistin-resistant bacteria
202 have not become widespread. However, in the CRE strains, the rate of colistin
203 resistance in CPE strains was higher than that in non-CPE strains. A previous study
204 reported a strong association between the presence of carbapenemase and increased
205 resistance to colistin in Enterobacteriaceae strains [17]. In addition, other investigators
206 have reported clonal spread of colistin resistance due to multiple mutational
207 mechanisms in CPE [19]. Since the number of CPE strains has been increasing in Japan,
208 it will be necessary to continually monitor the MIC of colistin in
209 carbapenemase-producing Enterobacteriaceae strains[20].

210 Nine *mcr* genes in ESBL-producing Enterobacteriaceae and CRE strains were
211 investigated in this study. The positive rate of *mcr* genes in all strains was 1.5%, which
212 was similar to that in other previous reports from clinical samples (0.2-3.2%) [8, 21-24].
213 Therefore, in Japan, it seems that *mcr* genes have not become widespread in bacteria.
214 One of the reasons for this is that colistin is currently used only in limited situations in
215 Japan [25]. On the other hand, large amounts of colistin have been used in animals
216 [26-28]. The first plasmid-mediated colistin resistance gene in Enterobacteriaceae,

217 *mcr-1*, was detected in food-producing animals and humans in China, and it is likely
 218 that *mcr-1*-mediated colistin resistance originated in animals and subsequently spread to
 219 people [8]. In addition, the presence of plasmids containing *mcr* genes in *E. coli* from
 220 livestock animals has previously been reported in Japan. In particular, a high prevalence
 221 of *mcr-1* and *mcr-5* has been observed among strains isolated from diseased pigs [11].
 222 Thus, we need to be wary of future spreading of *mcr* gene-positive strains in humans.
 223 The *mcr-1* and *mcr-9* are distributed worldwide, *mcr-4*, *mcr-2* and *mcr-8* are slightly
 224 distributed, and other *mcr* are limited[29]. In this study, we identified three *mcr-9*
 225 positive *Enterobacter cloacae* complex. Although the *Enterobacter cloacae* complex
 226 coharboring carbapenemase gene and *mcr-9* has previously reported in Japan[30],
 227 carbapenemase genes were not detected in the three *mcr-9* positive stains. We also
 228 identified one *mcr-5* positive *E. coli*, but there were no reports of *mcr-5* positive *E. coli*
 229 infecting humans in Japan. The patient infected with *mcr-5* gene-positive strain had
 230 recurrent urinary tract infection, but the patient had never been treated with colistin. The
 231 acquisition of *mcr* gene-positive strains in humans has been reported to be transmitted
 232 from livestock, but the patient had no history of contact with animals. There was a
 233 possibility that the *mcr-5*-positive strain resulted from meat consumption in this case
 234 because the number of *mcr-5* positive strains isolated in livestock was higher in Japan

235 than in other countries [11]. In this case, there was no history of treatment with colistin,
 236 whereas the patient was previously treated with levofloxacin and
 237 piperacillin-tazobactam. Since a previous study reported that the risk factors for
 238 *mcr*-positive Enterobacteriaceae were immunosuppression and history of antibiotic use,
 239 particularly carbapenems and fluoroquinolones [31], past use of levofloxacin may have
 240 been a risk factor for acquiring the *mcr*-5 positive strain in this patient.

241 Whole-genome sequencing analysis revealed that the *mcr*-5 positive strain was
 242 ST1642 and carried two distinct plasmids, the ESBL gene-carrying pN-ES-6-1 and
 243 *mcr*-5-carrying pN-ES-6-2. Although one study reported three *mcr*-1-harboring
 244 ESBL-producing *E. coli* ST1642 strains from bovine fecal samples[32], the
 245 *mcr*-5.1-harboring ESBL-producing *E. coli* ST1642 has not been reported previously.

246 We found transposons of TnShfr1 (Tn3-family) in the *mcr*-5 carrying *E. coli*. The
 247 *mcr*-5.1 gene is reportedly located on the Tn3-familiiy transposon of the *Salmonella*
 248 *enterica* Paratyphi B and *Cupriavidus gilardii* [33]. Therefore, there is a possibility that
 249 the *E. coli* strain received plasmid from these bacteria. In this study, the *mcr*
 250 genes-positive strain exhibited low MIC for colistin, which was not interpreted as
 251 resistant according to EUCAST. The results is the same as the previous reports [11, 34].

252 These results indicate that *mcr-5* and *mcr-9* may silently spread among
 253 Enterobacteriaceae, such as the stealth phenotype CPE [35].
 254 This study has some limitations. We investigated the prevalence of colistin-resistant
 255 and plasmid-mediated colistin resistance genes in ESBL-producing and CRE strains.
 256 Since *mcr*-positive strains were also detected in non-ESBL-producing and non-CRE
 257 strains [36], we need to perform surveillance in all Enterobacteriaceae including
 258 drug-sensitive strains. In addition, we did not investigate intrinsically resistance to
 259 colistin.

260 In conclusion, we revealed that the rates of colistin-resistance and *mcr*-positive strains
 261 are not high in Japan. Since the MIC for colistin was low in the *mcr-5* or *mcr-9*
 262 gene-positive strain, continuous monitoring of plasmid-mediated *mcr* genes in
 263 Enterobacteriaceae is necessary.

264

265 **Notes**

266 *Author contributions.*

267 NK, NA, KS, KK, YM, and KY contributed to study design and data interpretation. K
 268 I, YY, HM, MK, and KO contributed to study design and collection of isolates and data.
 269 N. K. provided expert advice, critically reviewed the manuscript, including for aspects

270 related to the English language, and contributed to its content. All authors reviewed and
271 approved the final version of the manuscript.

272 ***Disclaimer.***

273 The funders had no role in the design of the study, the collection or analysis of data, or
274 the decision to publish.

275

276 ***Financial support.***

277 This work was supported by the Japanese Society of Laboratory Medicine Fund for the
278 Promotion of Scientific and the Health and Labour Sciences Research Grants from the
279 Ministry of Health, Labour and Welfare, Japan (H28-Shinkou-Ippan-003).

280

281 ***Potential conflicts of interest.***

282 All authors: No reported conflicts of interest.

283

284 **References**

- 285 1. Takesue Y, Kusachi S, Mikamo H, et al. Antimicrobial susceptibility of pathogens
- 286 isolated from surgical site infections in Japan: Comparison of data from nationwide
- 287 surveillance studies conducted in 2010 and 2014-2015. *Journal of infection and*
- 288 chemotherapy : official journal of the Japan Society of Chemotherapy **2017**; 23:339-48.
- 289 2. Salah FD, Soubeiga ST, Ouattara AK, et al. Distribution of quinolone resistance gene
- 290 (qnr) in ESBL-producing *Escherichia coli* and *Klebsiella* spp. in Lomé, Togo.
- 291 *Antimicrob Resist Infect Control* **2019**; 8:104.
- 292 3. Pana ZD, Zaoutis T. Treatment of extended-spectrum β -lactamase-producing
- 293 *Enterobacteriaceae* (ESBLs) infections: what have we learned until now? *F1000Res*
- 294 **2018**; 7.
- 295 4. Suay-García B, Pérez-Gracia MT. Present and Future of Carbapenem-resistant
- 296 *Enterobacteriaceae* (CRE) Infections. *Antibiotics (Basel)* **2019**; 8.
- 297 5. Lee GC, Burgess DS. Treatment of *Klebsiella pneumoniae* carbapenemase (KPC)
- 298 infections: a review of published case series and case reports. *Ann Clin Microbiol*
- 299 *Antimicrob* **2012**; 11:32.

- 300 6. Mlynarcik P, Kolar M. Molecular mechanisms of polymyxin resistance and detection
301 of mcr genes. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub **2019**;
302 163:28-38.
- 303 7. Olaitan AO, Morand S, Rolain JM. Mechanisms of polymyxin resistance: acquired
304 and intrinsic resistance in bacteria. Frontiers in microbiology **2014**; 5:643.
- 305 8. Liu Y-Y, Wang Y, Walsh TR, et al. Emergence of plasmid-mediated colistin
306 resistance mechanism MCR-1 in animals and human beings in China: a microbiological
307 and molecular biological study. The Lancet Infectious Diseases **2016**; 16:161-8.
- 308 9. Sun J, Zhang H, Liu YH, Feng Y. Towards Understanding MCR-like Colistin
309 Resistance. Trends in microbiology **2018**; 26:794-808.
- 310 10. Kawanishi M, Abo H, Ozawa M, et al. Prevalence of Colistin Resistance Gene
311 mcr-1 and Absence of mcr-2 in Escherichia coli Isolated from Healthy
312 Food-Producing Animals in Japan. Antimicrobial Agents and Chemotherapy **2017**; 61.
- 313 11. Fukuda A, Sato T, Shinagawa M, et al. High prevalence of mcr-1, mcr-3 and mcr-5
314 in Escherichia coli derived from diseased pigs in Japan. International journal of
315 antimicrobial agents **2018**; 51:163-4.

- 316 12. Ohsaki Y, Hayashi W, Saito S, et al. First Detection of an Escherichia coli Strain
317 Harboring the mcr-1 Gene in Retail Domestic Chicken Meat in Japan. Japanese journal
318 of infectious diseases **2017**; 70:590-2.
- 319 13. Tada T, Uechi K, Nakasone I, et al. Emergence of a colistin-resistant Escherichia
320 coli clinical isolate harboring mcr-1 in Japan. Int J Infect Dis **2017**; 63:21-2.
- 321 14. Motoshima M, Yanagihara K, Morinaga Y, et al. Genetic diagnosis of
322 community-acquired MRSA: a multiplex real-time PCR method for Staphylococcal
323 cassette chromosome mec typing and detecting toxin genes. Tohoku J Exp Med **2010**;
324 220:165-70.
- 325 15. Rebelo AR, Bortolaia V, Kjeldgaard JS, et al. Multiplex PCR for detection of
326 plasmid-mediated colistin resistance determinants, mcr-1, mcr-2, mcr-3, mcr-4 and
327 mcr-5 for surveillance purposes. Euro surveillance : bulletin Europeen sur les maladies
328 transmissibles = European communicable disease bulletin **2018**; 23.
- 329 16. Borowiak M, Baumann B, Fischer J, et al. Development of a Novel mcr-6 to mcr-9
330 Multiplex PCR and Assessment of mcr-1 to mcr-9 Occurrence in Colistin-Resistant
331 Salmonella enterica Isolates From Environment, Feed, Animals and Food (2011-2018)
332 in Germany. Frontiers in microbiology **2020**; 11:80.

- 333 17. Bradford PA, Kazmierczak KM, Biedenbach DJ, Wise MG, Hackel M, Sahm DF.
334 Correlation of beta-Lactamase Production and Colistin Resistance among
335 Enterobacteriaceae Isolates from a Global Surveillance Program. Antimicrob Agents
336 Chemother **2015**; 60:1385-92.
- 337 18. Lee YL, Lu MC, Shao PL, et al. Nationwide surveillance of antimicrobial resistance
338 among clinically important Gram-negative bacteria, with an emphasis on carbapenems
339 and colistin: Results from the Surveillance of Multicenter Antimicrobial Resistance in
340 Taiwan (SMART) in 2018. International journal of antimicrobial agents **2019**;
341 54:318-28.
- 342 19. Otter JA, Doumith M, Davies F, et al. Emergence and clonal spread of colistin
343 resistance due to multiple mutational mechanisms in carbapenemase-producing
344 *Klebsiella pneumoniae* in London. Sci Rep **2017**; 7:12711.
- 345 20. Ohno Y, Nakamura A, Hashimoto E, et al. Molecular epidemiology of
346 carbapenemase-producing Enterobacteriaceae in a primary care hospital in Japan,
347 2010-2013. Journal of infection and chemotherapy : official journal of the Japan Society
348 of Chemotherapy **2017**; 23:224-9.

349 21. Quan J, Li X, Chen Y, et al. Prevalence of mcr-1 in Escherichia coli and Klebsiella
350 pneumoniae recovered from bloodstream infections in China: a multicentre longitudinal
351 study. *Lancet Infect Dis* **2017**; 17:400-10.

352 22. Zheng B, Xu H, Yu X, et al. Low prevalence of MCR-1-producing Klebsiella
353 pneumoniae in bloodstream infections in China. *Clin Microbiol Infect* **2018**; 24:205-6.

354 23. Chan WS, Au CH, Ho DN, Chan TL, Ma ES, Tang BS. Prospective study on human
355 fecal carriage of Enterobacteriaceae possessing mcr-1 and mcr-2 genes in a regional
356 hospital in Hong Kong. *BMC Infect Dis* **2018**; 18:81.

357 24. Wise MG, Estabrook MA, Sahm DF, Stone GG, Kazmierczak KM. Prevalence of
358 mcr-type genes among colistin-resistant Enterobacteriaceae collected in 2014-2016 as
359 part of the INFORM global surveillance program. *PLoS One* **2018**; 13:e0195281.

360 25. Hamada Y, Hirai J, Suematsu H, Yamagishi Y, Nicolau DP, Mikamo H. Clinical
361 experience with colistin in 9 Japanese patients with infection due to multi-drug
362 resistance pathogens. *The Japanese journal of antibiotics* **2016**; 69:319-26.

363 26. Catry B, Cavaleri M, Baptiste K, et al. Use of colistin-containing products within
364 the European Union and European Economic Area (EU/EEA): development of
365 resistance in animals and possible impact on human and animal health. *International*
366 *journal of antimicrobial agents* **2015**; 46:297-306.

367 27. Antimicrobial-resistant Bacteria Arising from the Use of Colistin Sulfate in the
368 Livestock (Antimicrobial-resistant Bacteria). Food Saf (Tokyo) **2017**; 5:24-8.

369 28. Makita K, Goto M, Ozawa M, et al. Multivariable Analysis of the Association
370 Between Antimicrobial Use and Antimicrobial Resistance in Escherichia coli Isolated
371 from Apparently Healthy Pigs in Japan. Microb Drug Resist **2016**; 22:28-39.

372 29. Ling Z, Yin W, Shen Z, Wang Y, Shen J, Walsh TR. Epidemiology of mobile
373 colistin resistance genes mcr-1 to mcr-9. J Antimicrob Chemother **2020**; 75:3087-95.

374 30. Kananizadeh P, Oshiro S, Watanabe S, et al. Emergence of carbapenem-resistant
375 and colistin-susceptible Enterobacter cloacae complex co-harboring bla(IMP-1) and
376 mcr-9 in Japan. BMC Infect Dis **2020**; 20:282.

377 31. Wang Y, Tian GB, Zhang R, et al. Prevalence, risk factors, outcomes, and molecular
378 epidemiology of mcr-1-positive Enterobacteriaceae in patients and healthy adults from
379 China: an epidemiological and clinical study. Lancet Infect Dis **2017**; 17:390-9.

380 32. Hassen B, Saloua B, Abbassi MS, et al. mcr-1 encoding colistin resistance in
381 CTX-M-1/CTX-M-15- producing Escherichia coli isolates of bovine and caprine origins
382 in Tunisia. First report of CTX-M-15-ST394/D E. coli from goats. Comp Immunol
383 Microbiol Infect Dis **2019**; 67:101366.

384 33. Borowiak M, Fischer J, Hammerl JA, Hendriksen RS, Szabo I, Malorny B.
385 Identification of a novel transposon-associated phosphoethanolamine transferase gene,
386 mcr-5, conferring colistin resistance in d-tartrate fermenting *Salmonella enterica* subsp.
387 *enterica* serovar Paratyphi B. *J Antimicrob Chemother* **2017**; 72:3317-24.

388 34. Tyson GH, Li C, Hsu CH, et al. The mcr-9 Gene of *Salmonella* and *Escherichia coli*
389 Is Not Associated with Colistin Resistance in the United States. *Antimicrob Agents*
390 *Chemother* **2020**; 64.

391 35. Shigemoto N, Kuwahara R, Kayama S, et al. Emergence in Japan of an
392 imipenem-susceptible, meropenem-resistant *Klebsiella pneumoniae* carrying blaIMP-6.
393 *Diagn Microbiol Infect Dis* **2012**; 72:109-12.

394 36. Sato T, Fukuda A, Usui M, et al. Isolation of a mcr-1-harboring *Escherichia coli*
395 isolate from a human clinical setting in Sapporo, Japan. *J Glob Antimicrob Resist* **2018**;
396 13:20-1.

397

Table 1. Colistin resistance in ESBL-producing and CRE strains

Organisms	Colistin-resistance		Carbapenemase genes (number)	<i>mcr</i> genes (number)
	n	(%)		
ESBL-producing strains (180)	2	(1.1 %)		
<i>Escherichia coli</i> (147)	1	(0.68 %)	N.D.	<i>mcr-5</i> (1)
<i>Klebsiella pneumoniae</i> (28)	1	(3.6 %)	N.D.	N.D.
<i>Klebsiella oxytoca</i> (5)	0	(0.0%)	N.D.	N.D.
CRE strains (93)	19	(20.4%)		
<i>Citrobacter</i> spp. (2)	0	(0.0%)	N.D.	N.D.
<i>Escherichia coli</i> (2)	0	(0.0%)	N.D.	N.D.
<i>Enterobacter cloacae</i> complex (36)	18	(50.0%)	IMP-1 group (6)	<i>mcr-9</i> (3)
<i>Klebsiella aerogenes</i> (42)	1	(2.4%)	IMP-1 group (1)	N.D.
<i>Klebsiella pneumoniae</i> (11)	0	(0.0%)	IMP-1 group (7), NDM and OXA-48 (1)	N.D.
Total (273)	21	(7.7%)		

N.D., not detected

Table 2. Inc groups and antimicrobial resistance genes of *mcr-5* gene positive strain

Plasmid	Size(bp)	Inc groups	Resistance gene	Identity (%)	Query / Template length	Position in contig	Accession number
pN-ES-6-1	94,901	IncFIA	<i>mph(A)</i>	100	906/906	15559..16464	D16251
		IncFIB	<i>dfrA17</i>	100	474/474	21482..21955	FJ460238
		IncQ1	<i>bla</i> _{TEM-1B}	100	861/861	41557..42417	AY458016
			<i>sul2</i>	100	816/816	45621..46436	HQ840942
			<i>tet(B)</i>	100	1206/1206	24758..25963	AF326777
			<i>aac(3)-Ild</i>	99.88	860/861	11179..12039	EU022314
			<i>aac(3'')-Ib</i>	100	804/804	46497..47300	AF321551
			<i>aph(6)-Id</i>	100	837/837	47300..48136	M28829
pN-ES-6-2	79,974	IncF II	<i>mcr-5.1</i>	100	1644/1644	6837..8480	KY807921

400 **Figure Legends**

401 **Figure 1.** The Distribution of colistin minimum inhibitory concentration (MIC) in
402 ESBL producing strains and CRE strains, Japan, August 2016- March 2017 (A). B) The
403 comparison of colistin resistance rates between non-CPE and CPE. The MICs of
404 colistin were measured using microdilution method. Blue indicates no-colistin resistant;
405 red, colistin resistant.

406
407 **Figure 2.** Structure of plasmid pN-ES-6-1 and pN-ES-6-2 from *Escherichia coli*.
408 Yellow green indicates antimicrobial resistant; gray, hypothetical protein; red, insertion
409 sequence; green, plasmid replication; purple, other protein.

410
411 **Figure 3.** Comparison of *mcr-5*-carrying plasmid. A) Phylogenetic tree of
412 *mcr-5*-carrying plasmid from *Salmonella enterica* (Gene accession no. NC_003277.2),
413 *Salmonella enterica* (Gene accession no. LC488708.01), *Escherichia coli* (Gene
414 accession no. BENI01000099.1), pN-ES-6-2 *Escherichia coli* and *Salmonella enterica*
415 (Gene accession no. KY807921.1). Arrow represent coding sequences (gray arrows,
416 *mcr-5*) and indicated direction of transcription. B) The genetic environment of *mcr-5*

417 from *Salmonella enterica* (Gene accession no. KY807921.1), *Escherichia coli* (Gene
418 accession no. BENI01000099.1) and pN-ES-6-2 *Escherichia coli*.

Figure 1.

A

B

Figure 3.